Core Viewpoint - Hendi Pharmaceutical has obtained the drug registration certificate for Ibuprofen suspension from the National Medical Products Administration as of June 2025, and is currently preparing for product launch and sales [1] Company Developments - The company is actively working on the preliminary preparations for the product's market launch following the receipt of the registration certificate [1] - The impact of the product registration on the company's operating performance is not expected to be significant in the short term [1] Market Considerations - Future revenue generation from the product is uncertain due to factors such as non-uniqueness of the product, competition from similar products, and the effectiveness of the company's business promotion and sales scale [1]